懷特生技新藥股份有限公司 Approved
最後更新時間 2025/07/11 , 01:27 AM
最後更新時間 2025/07/11 , 01:27 AM
負責人
Li,Yi-Li
統一編號
16766281
成立日期
1998/11/24
資本額
NT$3,000,000,000
實收資本額
NT$1,986,188,790
股票代號
4108
電話
02-2545-3697
地址
5-1F, No. 167, Fusing N. Rd., Songshan Dist., Taipei City, 105, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Li,Yi-Li Chairman 17.69% MAYWUFA COMPANY LTD.
Li,Yi-Ling Vice Chairman 0.10%
Li,Cheng-Jia Director 17.70% MAYWUFA COMPANY LTD.
Lai,Yu-Ru Director 17.69% MAYWUFA COMPANY LTD.
Vacancy Director 0.02% LI LING INVESTMENT CO., LTD.
Cai,Jing-Zhong Director 0.02% HUA WEI Ltd.
Wang,Ming-Fu Director 0.02% HUA WEI Ltd.
Huang,Ze-Hong Director 0.03% REN YU Ltd.
Wang,Bai-Sen Director 0.03% REN YU Ltd.
Wang,De-Shan Independent Director 0.00%
Lai,Shan-Gui Independent Director 0.00%
Lin,Shui-Long Independent Director 0.00%
Wu,Yong-Chang Independent Director 0.00%
營業項目
  • Retail Sale of Pharmaceutical and Medical Goods in Specialized Stores(475112)
  • Wholesale of Other Food(454920)
  • Wholesale of Pharmaceutical and Medical Goods(457112)
  • Manufacture of Drugs and Medicines(200211)
  • 公司歷程
  • Change Person in Charge to Li,Yi-Li
    2020/09/07
  • Change Capital to 3,000,000,000
    2019/06/27
  • Change Capital to 2,000,000,000
    2012/12/04
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 30,538 153,562 162,489
    Operating cost 20,694 89,555 94,846
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 9,844 64,007 67,643
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 9,844 64,007 67,643
    Operating expenses 43,418 224,190 189,320
    Other gain (loss), net - - -
    Operating profit (loss) -33,574 -160,183 -121,677
    Non-operating income and expenses 5,095 51,649 47,530
    Net profit (loss) before tax -28,479 -108,534 -74,147
    Income tax expense (benefits) 0 0 0
    Net profit (loss) of ongoing business for the current period -28,479 -108,534 -74,147
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -28,479 -108,534 -74,147
    Other comprehensive profit (loss), net -8,804 46,388 65,211
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -37,283 -62,146 -8,936
    Net profit (loss) attributable to owners of parent company -14,588 -73,501 -47,117
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests -13,891 -35,033 -27,030
    Comprehensive profit (loss) attributable to owners of parent company -20,054 -30,438 18,536
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests -17,229 -31,708 -27,472
    Basic earnings per share (yuan) 0 0 0
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -29,817 -50,134 -54,772
    Net cash inflows (outflows) from investing activities 57,980 -135,137 26,249
    Net cash inflow (outflow) from financing activities -2,806 145,238 -9,177
    Effect of Exchange Rate Changes on Cash and Cash Equivalents - - -
    Increase (decrease) in cash and cash equivalents in the current period 25,357 -40,033 -37,700
    Beginning balance of cash and cash equivalents 22,723 62,756 100,456
    Ending balance of cash and cash equivalents 48,080 22,723 62,756
    項目 2025 2024 2023
    Current asset 1,528,389 1,306,393 1,499,456
    Non-current asset 867,143 1,133,277 851,055
    Total asset 2,395,532 2,439,670 2,350,511
    Current liability 45,645 54,396 57,378
    Non-current liability 18,606 16,894 22,471
    Total liability 64,251 71,290 79,849
    share capital 1,986,189 1,986,189 1,986,189
    Equity - secruity token - - -
    capital reserve 5,912 5,853 1,161
    retained earning -238,448 -264,607 -191,106
    Other equity 127,712 173,925 130,862
    Treasury stock - - -
    Total equity attributable to owners of parent company 1,881,365 1,901,360 1,927,106
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests 449,916 467,020 343,556
    Total Equity 2,331,281 2,368,380 2,270,662
    Share capital awaiting retirement (unit: share) - - -
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 9 9 9
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額 0
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額 0
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    2024 01-04 0~0.5M 0M
    2023 01-12 0.5~1M 0M
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    商標
  • 歐疼寧
  • 歐樂解
  • 歐樂芬
  • 懷特胺速
  • ProAA
  • rAPP
  • 大皇耆
  • 皇耆
  • AmazPower
  • rAPS
  • 專利
  • 黃耆萃取物用於抑制SARS-CoV-2病毒入侵以及治療COVID-19相關的細胞風暴的用途
  • 黃耆多醣萃取物在製備用於增強癌症免疫療法的功效的藥物的用途
  • 具有延長黃耆功效保存及抗黴菌的包裝袋結構
  • 具提升溶解力與吸收率之黃耆多醣晶體顆粒結構
  • 美迪紫檀素、其衍生物及製造方法
  • 預防和治療老化的黃耆醫藥組合物及其應用
  • 以包含黃耆萃取物之組成物治療自發性血小板缺少性紫斑症之技術
  • 增進胰島素敏感性與治療糖尿病之醫藥組合物
  • 政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Others
    2010, 2012
  • Profit-seeking Enterprise Income Tax
    2010, 2011
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    2018/10/03 Paragraph 2, Article 32 of the Labor Standards Act
    2016/01/19 Paragraph 1, Article 32 of the Labor Standards Act
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。